Abstract

Insulin secretion by pancreatic beta-cells is stimulated by glucose, amino acids, and other metabolic fuels. Glutamate dehydrogenase (GDH) has been shown to play a regulatory role in this process. The importance of GDH was underscored by features of hyperinsulinemia/hyperammonemia syndrome, where a dominant mutation causes the loss of inhibition by GTP and ATP. Here we report the effects of green tea polyphenols on GDH and insulin secretion. Of the four compounds tested, epigallocatechin gallate (EGCG) and epicatechin gallate were found to inhibit GDH with nanomolar ED(50) values and were therefore found to be as potent as the physiologically important inhibitor GTP. Furthermore, we have demonstrated that EGCG inhibits BCH-stimulated insulin secretion, a process that is mediated by GDH, under conditions where GDH is no longer inhibited by high energy metabolites. EGCG does not affect glucose-stimulated insulin secretion under high energy conditions where GDH is probably fully inhibited. We have further shown that these compounds act in an allosteric manner independent of their antioxidant activity and that the beta-cell stimulatory effects are directly correlated with glutamine oxidation. These results demonstrate that EGCG, much like the activator of GDH (BCH), can facilitate dissecting the complex regulation of insulin secretion by pharmacologically modulating the effects of GDH.

Highlights

  • Summary of the effects of EGCG on the reductive amination reaction As shown here, EGCG has marked effects on both the y-intercept and the slope of the curves and infers that EGCG inhibits in a non-competitive manner

  • Because green tea was suggested as a therapeutic agent for the treatment of diabetes more than 70 years ago [23] and because of the role that GDH plays in insulin secretion, the effects of green tea catechins on GDH were tested in vitro

  • Because all four polyphenols have comparable antioxidant activities [24], this strongly suggests that EGCG and ECG effects are allosteric in nature

Read more

Summary

Objectives

Our goal was to find a nontoxic pharmacological agent that could be used to test these models and assess whether GDH might be an appropriate target in the treatment of disorders of glucose homeostasis

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call